Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dicks Sporting Goods Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Dicks Sporting Goods Inc trades at $217.98 (market cap $19.51B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays a 2.29% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DKS | |
|---|---|---|
Market Cap | $39.89B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $239.17 |
52-Week Low | $278.09 | $187.78 |
Enterprise Value | $38.15B | $26.30B |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DKS trades at $217.98, up 0.3% on the day, with a bearish technical signal but strong fundamentals including a 6% comps growth in Q1 2026 and three consecutive quarterly earnings beats. Recent developments include the launch of the ScoreCard+ loyalty program and a partnership with Lids to expand fan merchandise in over 100 stores by late summer 2026. The stock shows robust profitability with a 20.9% ROE and a 4.71% net income margin, supported by $1.17B net income in 2025.
The outlook is positive with a consensus price target of $261, representing 19.7% upside, and no sell ratings among 64 analysts. Key risks include ongoing shareholder litigation over fiduciary duties and competitive pressures in sporting goods retail. The stock presents a growth opportunity driven by strategic expansions and consistent earnings performance, though investors should monitor legal developments and market share sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
